Eric Venker

Roivant CEO Eric Venker sells 200,000 shares for $6.6M on scheduled 10b5-1 plan; retains 1,613,063 shares plus 4,244,834 stock options

Eric Venker, President & Immunovant CEO, executed 2 separate sales totaling 200,000 shares for $6,631,267.64 at a blended average price of $33.16 on 2026-06-24 as part of a pre-arranged 10b5-1 trading plan. His non-derivative holdings post-transaction stand at 1,613,063 shares, representing an 11.0% reduction from pre-transaction levels, though his derivative holdings of 4,244,834 stock options remain intact. Roivant's fundamentals remain challenged, with net income of $-265,891,000.00 in the latest fiscal year and annual revenue growth of -71.6%, yet the stock has appreciated 15.2% over the past 30 days and 28.5% over 90 days—substantially outperforming his historical cross-ticker average 90-day return of 31.8% after sells. The scheduled nature of this trade via 10b5-1 plan removes discretionary timing as a signal factor.

ROIV President Eric Venker sells 200,000 shares at $30.27; scheduled 10b5-1 plan. Holds 1.61M post-sale.

Eric Venker, President & Immunovant CEO, sold 200,000 shares at $30.27 on 2026-05-22 as part of a pre-arranged 10b5-1 trading plan. This is a scheduled, non-discretionary transaction. His holding dropped from 1.81M to 1.61M shares (-11.0% vs pre-transaction holdings). The company is unprofitable with annual revenue growth of -71.6%, though the stock trades within its 52-week range at $29.96 current price. Prior same-ticker sales at ROIV show mixed 30/90-day post-sale price performance (ranging from +0.2% to +22.3% over 30 days), and cross-ticker selling history averaged 90-day returns of +31.3%. The scheduled nature of this transaction limits inference about insider sentiment; it reflects pre-planned execution rather than discretionary decision-making.

Venker Eric (then-CEO of Immunovant) sold 200,000 shares of ROIV at $29.59 under 10b5-1 plan

Eric Venker, who was President & Immunovant CEO at the time of filing, sold 200,000 shares for $5,918,000.00 on 2026-04-20 pursuant to a pre-arranged 10b5-1 trading plan, reducing his holdings from 1,847,546 shares to 1,647,546 shares (a 10.8% reduction in position). As a scheduled transaction executed under a Rule 10b5-1 plan rather than a discretionary choice, this sale does not reflect timing-based decision-making by the insider. The transaction represents a moderate portfolio adjustment and warrants standard monitoring as part of tracking insider holdings changes, though the pre-arranged nature limits what can be inferred about insider sentiment regarding near-term stock performance.

Venker, then-President & CEO of Immunovant, sold 200,000 shares of ROIV at $28.24 via 10b5-1 plan

Venker Eric, who was President & CEO of Immunovant at the time of this transaction, sold 200,000 shares on 2026-03-17 at $28.24 as part of a pre-arranged 10b5-1 trading plan, resulting in a $5.6M proceeds and reducing his holdings from 1.85M shares to 1.65M shares. Because this sale was scheduled under a 10b5-1 plan rather than discretionary, it does not reflect a contemporaneous investment decision or timing choice. The -10.8% reduction in his holdings occurs within the framework of a predetermined trading schedule, which limits the inferential weight an investor should place on the transaction as a signal of conviction or concern about the stock's prospects.

CEO Eric Venker sells 200,000 shares of ROIV at $26.49; stock at 52-week high, company deeply unprofitable (-$265.9M net income).

Eric Venker, President & CEO, sold 200,000 shares (10.8% of his then-holdings) on 2026-02-13 at $26.49, reducing his position from 1.85M to 1.65M shares. The transaction occurred as ROIV traded near its 52-week high of $27.67 and has appreciated 35.6% over the prior 90 days and 18.8% over the prior 30 days. Notably, Venker's cross-ticker track record shows a 90-day well-timed rate of 0.00%, meaning his prior 20 sells across all tickers did not precede declines—the stock typically continued rising after his dispositions. At ROIV specifically, his 5 prior trades include one measurable 90-day outcome (November 2025 sale followed by +4.6% return), indicating the stock rose after that prior sale as well. Against this backdrop, the company is severely unprofitable (net income of $-265,891,000.00 for the most recent fiscal year) and posted only $1,999,000.00 in latest-quarter revenue alongside a -76.7% annual revenue decline, creating a structural tension between deteriorating fundamentals and elevated share price.

Venker Eric, then-CEO of Immunovant, sold 200,000 shares of ROIV at $21.92 per share via 10b5-1 plan

Venker Eric, who was President & CEO of Immunovant at the time of filing, sold 200,000 shares (200.0K shares) of Roivant Sciences Ltd. at $21.92 on 2026-01-12 for a total value of $4,384,000.00 ($4.4M), reducing his holdings from 1,854,597 shares (1.85M shares) to 1,654,597 shares (1.65M shares), a reduction of 10.8% of his pre-transaction position. This sale was executed under a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary. Following the sale, he retained 1,654,597 shares (1.65M shares), indicating a substantial ongoing stake in the company despite the disposition.

Venker (then-CEO of Immunovant) sold 200,000 ROIV shares at $20.85 via pre-arranged 10b5-1 plan

Venker Eric, who was President & CEO of Immunovant at the time of filing, sold 200,000 shares of Roivant Sciences Ltd. at $20.85 on 2025-12-09 for $4,170,000, reducing his holdings to 1,497,908 shares from 1,697,908 shares. This sale was executed under a pre-arranged 10b5-1 trading plan adopted on 2025-03-28, meaning it was scheduled rather than discretionary. The execution of a scheduled plan does not carry signal about current market or company conviction. Investors should note that Venker is no longer the issuer's current CEO per the most recent SEC filing, though he held that role at the time of this transaction.

Immunovant former CEO Venker sells 200,000 ROIV shares at $20.22 via pre-arranged 10b5-1 plan adopted 2025-03-28.

Venker Eric, who was President & Immunovant CEO, sold 200,000 shares of Roivant Sciences Ltd. at $20.22 on 2025-11-07, reducing his holdings from 1,704,959 shares to 1,504,959 shares (a -11.7% reduction in his position). This transaction was executed under a pre-arranged 10b5-1 trading plan adopted on 2025-03-28, meaning it was scheduled and not subject to discretionary timing decisions by the insider. The sale generated $4,044,000.00 in proceeds. Since the transaction followed a formal pre-arrangement, it does not reflect a real-time decision by Venker about the stock's direction or his confidence in the company at this specific moment.

Venker Eric (then-CEO, Immunovant) sold 851,383 shares for $14,467,502.37 in 3 transactions via 10b5-1 plan

Venker Eric, who was President & Immunovant CEO at the time of filing, executed 3 separate sales totaling 851,383 shares for $14,467,502.37 between October 15–17, 2025, at prices ranging from $16.93 to $17.06 (blended average $16.99). This transaction was part of a pre-arranged 10b5-1 trading plan adopted on 2025-03-28, meaning it was scheduled rather than discretionary. Post-transaction holdings of 1,504,959 shares represent a 36.1% reduction from his pre-transaction position of 2,356,342 shares. Since the sale was scheduled under a 10b5-1 plan, it reflects a commitment made months earlier and carries no signal about current market or business conditions. Investors should note the significant scale of the position reduction and monitor whether the remaining 1.50M share position continues under any additional scheduled plans.

Venker Eric (then-CEO of Immunovant) sells 125,667 shares for $2,047,335.75 via pre-arranged 10b5-1 plan

Venker Eric, who was President & Immunovant CEO at the time, executed 2 separate sales totaling 125,667 shares for $2,047,335.75 at an average price of $16.29 per share on 2025-10-09 and 2025-10-13. The sales reduced his holdings from 1,630,626 shares to 1,504,959 shares, representing a -7.7% reduction in his position. This transaction was part of a pre-arranged 10b5-1 trading plan adopted on 2025-03-28, making it a scheduled, non-discretionary event rather than a discretionary insider decision. The routine nature of a 10b5-1 execution and the modest percentage reduction in holdings limit the informational significance of this filing for assessing management conviction or concerns about valuation.